Checkpoint blockade in esophagogastric cancer Journal Article


Authors: Cohen, N. A.; Strong, V. E.; Janjigian, Y. Y.
Article Title: Checkpoint blockade in esophagogastric cancer
Abstract: There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second-line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD-1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second-line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma. © 2018 Wiley Periodicals, Inc.
Keywords: protein expression; treatment response; review; advanced cancer; drug efficacy; antineoplastic agent; adenocarcinoma; cancer immunotherapy; randomized controlled trials as topic; pathology; monoclonal antibody; immunology; antibodies, monoclonal; immunotherapy; stomach cancer; cytotoxic t lymphocyte antigen 4; esophagus cancer; stomach neoplasms; gastroesophageal; stomach tumor; pd-1; esophagogastric junction; programmed death 1 ligand 1; programmed death 1 receptor; randomized controlled trial (topic); gastric; gastroesophageal junction; ctla-4 antigen; nivolumab; humans; human; priority journal; checkpoint inhibitor; antagonists and inhibitors; pdcd1 protein, human; programmed cell death 1 receptor; cd274 protein, human; b7-h1 antigen; ctla4 protein, human
Journal Title: Journal of Surgical Oncology
Volume: 118
Issue: 1
ISSN: 0022-4790
Publisher: Wiley Blackwell  
Date Published: 2018-07-01
Start Page: 77
End Page: 85
Language: English
DOI: 10.1002/jso.25116
PUBMED: 29878357
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 October 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Yelena Yuriy Janjigian
    148 Janjigian
  2. Vivian Strong
    148 Strong
  3. Noah Avram Cohen
    16 Cohen